Madrigal Pharmaceuticals (MDGL) Operating Leases (2019 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Operating Leases of $5.9 million for Q2 2026, up 30.92% year-over-year from $4.5 million in Q2 2025, and up 12.09% quarter-over-quarter from $5.3 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Operating Leases (2019 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Operating Leases for 8 consecutive years, with $5.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Leases rose 30.92% year-over-year to $5.9 million; the TTM figure through Jun 2026 stood at $5.9 million (up 30.92% YoY), while the FY2025 annual figure was $6.7 million, up 561.2% from the prior year.
- Operating Leases advanced to $5.9 million in Q2 2026 per MDGL's latest filing, from $5.3 million in the prior quarter.
- Across five years, Operating Leases topped out at $6.7 million in Q4 2025 and bottomed at $71000.0 in Q3 2022.
- Historically, Operating Leases has averaged $2.4 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases plunged 85.54% — and 2023, when it soared 1763.38%.
- Madrigal Pharmaceuticals' Operating Leases stood at $71000.0 in 2022, then soared by 1570.42% to $1.2 million in 2023, then declined by 14.17% to $1.0 million in 2024, then surged by 561.2% to $6.7 million in 2025, then decreased by 12.0% to $5.9 million in 2026.
- Business Quant data shows MDGL's Operating Leases at $5.9 million in Q2 2026, $5.3 million in Q1 2026, and $6.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.92 Mn |
| Mar 31, 2026 | 5.28 Mn |
| Dec 31, 2025 | 6.73 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 4.52 Mn |
| Mar 31, 2025 | 750,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 1.19 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 178,000.00 |
| Mar 31, 2022 | 283,000.00 |
| Dec 31, 2021 | 387,000.00 |
| Sep 30, 2021 | 491,000.00 |
| Jun 30, 2021 | 594,000.00 |
| Mar 31, 2021 | 387,000.00 |
| Dec 31, 2020 | 468,000.00 |